Infusion pump technology for subcutaneous prostacyclin analog therapy has improved, with improved user experiences, simplified priming processes, easier filling, capability for lower doses, and better safety alerts and alarms. This may allow more pulmonary arterial hypertension (PAH) patients to safely manage and benefit from subcutaneous prostacyclin analogs. Read the Advances in Therapy commentary

Secreted phosphoprotein 1 (SPP1) levels were higher in patients with PAH, and SPP1 levels were associated with disease severity. Patients who had postpartum adverse events had higher SPP1 concentrations. SPP1 may act as a predictor of adverse postpartum events for people with pulmonary arterial hypertension (PAH), along with other clinical indicators. Read the European Journal of Obstetrics and Gynecology and Reproductive Biology article

A survey of 200 people in the United States living with pulmonary arterial hypertension (PAH) found that 85% had never discussed palliative care with their healthcare provider, even though nearly nine in 10 said they would feel comfortable doing so. Many participants mistakenly thought palliative care was only for end-of-life care, highlighting the need for better conversations so people understand how it can help manage symptoms and improve quality of life throughout their illness. Read the...